What is on the record, and how little there is
Amble sells compounded semaglutide and tirzepatide through a telehealth platform. It advertises availability in all fifty states and prices each drug at a rate that stays put as the dose climbs. It says that figure already covers the drug itself, the injection supplies, and delivery. That is very close to the complete public record.
That is a finding, not a complaint about a site being hard to navigate. Amble publishes a price and a coverage claim. It does not name the compounding pharmacy. It displays no third-party accreditation seal. It does not publish how intake works or what happens when a patient wants to cancel. Four separate absences, taken together, describe a provider that has said what it costs and almost nothing about what it is.
Be precise about what an absence means. Amble does not publish these disclosures, which is not the same as saying the answers do not exist — a reader who calls may well get them. What a prospective patient cannot do is find them on the public record before handing over their information, which is the point at which they are actually needed.
The flat rate, and the word 'starting'
On structure alone, Amble is fine. It uses the pricing shape this comparison generally rewards: one rate per drug, holding across doses, so climbing a titration schedule leaves the monthly number where it started. Bundling supplies and shipping into that figure removes the small charges that otherwise add up to a meaningful annual difference.
The qualifier is where the care is needed. Both of Amble's figures are 'starting at' prices, and on tirzepatide the site states that the range runs higher than the figure it leads with. A starting price is a floor, not a quote. A reader comparing Amble's floor against another provider's actual rate is not making a comparison. They are reading two different kinds of number side by side.
That is why every figure here carries its qualifier, and on Amble the qualifier is the most load-bearing thing about the price. Before enrolling, get a quote for your own situation. Compare that against what the other providers here charge, rather than comparing the advertised entry point.
Why the missing pharmacy name matters more here
In a record with this little in it, the unnamed compounding pharmacy stops being one gap among many and becomes the defining one. A patient buying a compounded medication has one question that outranks the rest: who prepared what is in this vial. Amble does not answer it. There is no accreditation seal, no named clinical leadership, and no published process detail to fall back on instead.
Compare that with what the better-documented providers in this comparison publish. At least one names more than one compounding pharmacy outright, several name their operating entity, and several display a seal. Those disclosures cost a company nothing except the willingness to be checked, which is exactly why their absence carries information.
As with every compounded product in this comparison, compounded semaglutide and tirzepatide are prepared by a compounding pharmacy and are not FDA-approved finished drug products. Amble does not publish a brand-name option.
Where Amble fits
Amble belongs in an early price comparison. Its figures are published and its coverage claim is broad. Its structure is straightforward enough to sit in a table beside the rest of this set without a footnote. That holds as long as the 'starting at' qualifier travels with the number.
It does not belong at the end of a shortlist without a phone call first. Which pharmacy, what the intake involves, what cancelling costs, what the tirzepatide rate is for your own dose: Amble leaves all of it to a conversation. That is a legitimate way to run a business. It is also a reason to have the conversation before the payment rather than after.
Amble's published pricing
compareglp may earn a commission when a reader signs up with a provider through a link on this site. None of the 16 providers reviewed here are paid partners today. See how this works.
See Amble's current price →Good fit if
- Readers building an initial price comparison who want a published flat rate in the table alongside the rest of this set.
- Patients who expect to titrate up and want a rate that does not climb with the dose.
- Readers who would rather have the drug, the supplies, and delivery folded into a single figure than itemized later.
- People willing to call and confirm the program details before enrolling rather than expecting to find them published.
Look elsewhere if
- Anyone who wants to know which pharmacy compounds their medication. Amble does not name one, and there is no accreditation seal to fall back on either.
- Readers taking the tirzepatide headline at face value — it is a starting figure, and Amble's own site says the range runs higher.
- Patients who want the cancellation and intake terms in writing before paying. Amble does not publish them.
- Anyone who treats a thin public record as itself a reason for caution. Several providers in this comparison publish considerably more, at no cost to the reader.
How this review was verified
- Read Amble's published pricing at its source URL and logged each figure with the date it was read.
- Noted that both published figures are 'starting at' prices, and that Amble's own site states the tirzepatide range runs above the figure it leads with. That qualifier is attached to the number wherever it appears.
- Checked the site for the name of the compounding pharmacy, for a displayed third-party accreditation seal, and for published intake and cancellation terms. None of the four appears on the public record.
- Took Amble's own wording for what the quoted figure covers — the drug, the injection supplies, and delivery — rather than inferring the scope of the figure.
- Checked the advertised state availability against all fifty states, and screened the entity behind the brand against the FDA warning letter record, which shows no letter for Amble.